Juvenile Arthritis


FDA Approves Treatment for Still's Disease

July 14, 2020

The U.S. FDA has approved the first treatment for adult-onset Still's disease, a rare form of systemic juvenile idiopathic arthritis associated with high fever, arthritis and rash.

Tocilizumab May Help Uveitis in Juvenile Idiopathic Arthritis

March 03, 2020

Tocilizumab might be a useful adjunctive therapeutic option for children with juvenile idiopathic arthritis-associated uveitis that doesn't respond to TNFi treatment, say researchers recently writing in The Lancet Rheumatology.

Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

JIA Disease Activity Persists, Despite Lower Uveitis, Major Joint Surgery Rates

November 27, 2019

While the need for orthopedic surgery and the presence of uveitis have diminished over the past 20 years in children with juvenile idiopathic arthritis (JIA), disease activity is present more than 50 percent of the time, say researchers recently writing in Arthritis Research and Therapy.

One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis

November 18, 2019

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

ACR Annual Meeting Roundup: Higher death rates in lupus

November 14, 2019

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.

Abatacept Monotherapy Effective in JIA

November 10, 2019

ACR Annual Meeting:  Monotherapy with abatacept was safe and effective in patients with polyarticular juvenile idiopathic arthritis who couldn’t tolerate or didn’t respond to methotrexate, researchers reported November 11 at the annual meeting of the American College of Rheumatology in Atlanta.

Rheumatology Nurses Society Meeting Roundup: JIA, a Missed Diagnosis and More

September 13, 2019

From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month. 

Tips for Transitioning a Juvenile Idiopathic Arthritis Patient to Adult Care

September 09, 2019

Better communication between pediatric and adult rheumatologists is especially important as pediatric patients with juvenile idiopathic arthritis transition to adult care.  In this Q&A, we revisit a Rheumatology Nurses Society annual meeting presentation made last month by Cathy Patty-Resk, MSN, RN, CPNP, a pediatric rheumatology nurse practitioner with the Children’s Hospital of Michigan.

Nearly 5% of Children on Biologics Develop Hypersensitivity Reactions, Study Shows

August 21, 2019

Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month

Etanercept Trial Supports Use for JIA, ERA and PsA

June 10, 2019

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

Etanercept Biosimilar Approved for RA and Other Conditions

June 07, 2019

In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.

New Guidelines Recommend Early Treatment with DMARDs for JIA Polyarthritis

May 31, 2019

Early treatment with DMARDs for juvenile idiopathic arthritis polyarthritis is now preferred over beginning patients on NSAID monotherapy, per updated treatment guidelines. 

ACR Updates Juvenile Arthritis Treatment Recommendations

May 31, 2019

The American College of Rheumatology and the Arthritis Foundation have updated the 2013 treatment guidelines for juvenile idiopathic arthritis (JIA), which includes juvenile  non-systemic  polyarthritis,  sacroiliitis, and enthesitis. In this slideshow, we highlight the recommendations.

Conventional Treatment Shows Some Efficacy in Juvenile Idiopathic Arthritis

May 20, 2019

Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.

Treatment Options for Complex Cases of Juvenile Idiopathic Arthritis

May 09, 2019

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.

Trials for Early Onset JIA Treatment Show Promise

March 04, 2019

Historically, treatments for children with systemic juvenile idiopathic arthritis (sJIA) have been difficult and ineffective, leading to poor outcomes. But, findings from a new study point to a method that could lead to more positive results.

6 New Medications for Rheumatology in 2018

December 21, 2018

Here’s a brief look at 6 medications for rheumatologic disorders that were newly approved in the second half of 2018.

Wearable Devices for Rheumatology: Ready for Prime Time?

November 21, 2018

The benefits and limitations of current technology and a look ahead to future advances.

Updated ACR Treatment Guidelines for Juvenile Idiopathic Arthritis

October 24, 2018

New guidelines have been drafted for the treatment of JIA, specifically addressing therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis.